Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01790490 · ClinicalTrials.gov registry record · Phase 2
Glutamatergic Modulation of Cocaine-related Deficits
A Phase 2 study of Cocaine Dependence, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT01790490: Completed Phase 2 study of Cocaine Dependence, sponsored by New York State Psychiatric Institute.
NCT01790490 is a Phase 2 study of Cocaine Dependence that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 8 participants, below the 298-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01790490, a Phase 2 study of Cocaine Dependence, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
Cocaine dependence involves problematic neuroadaptations, such as heightened reactivity to cocaine cues, that may be responsive to pharmacological modulation of glutamatergic circuits. Despite promising preclinical findings with n-methyl-d-aspartate receptor (NMDAr) modulators, studies with human subjects have been unsuccessful to date. The purpose of this investigation is to examine the effects of the NMDAr antagonist ketamine, recently found to have potent therapeutic effects in humans, on cue-induced craving and impaired motivation for quitting cocaine in cocaine dependent participants, 24-hours post-infusion.
Primary Outcome
Serial visual analogue scale (VAS) scores for craving elicited by cocaine cue: units on a scale (0-200), high is worse. Scores are obtained at baseline and at 24 hours after the infusion.
Conditions Studied
Interventions
- DRUG Ketamine 0.41 mg/kg
- DRUG Ketamine 0.71 mg/kg
- DRUG Lorazepam 2 mg
Study Locations (1)
New York
- NYSPI - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
What the finished NCT01790490 record still lists
NCT01790490 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 298-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Cocaine Dependence appearing as the primary indexed condition, and to 3 interventions - of which Ketamine 0.41 mg/kg is the first listed.
NCT01790490 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01790490 about?
NCT01790490 is a clinical study titled "Glutamatergic Modulation of Cocaine-related Deficits". Cocaine dependence involves problematic neuroadaptations, such as heightened reactivity to cocaine cues, that may be responsive to pharmacological modulation of glutamatergic circuits. Despite promising preclinical findings with n-methyl-d-aspartate receptor (NMDAr) modulators, studies with human su...
What is the current status of trial NCT01790490?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2011-02. Estimated completion is 2012-03.
What conditions does trial NCT01790490 study?
This clinical trial studies the following conditions: Cocaine Dependence.
What interventions are being tested in trial NCT01790490?
The interventions under investigation include: Ketamine 0.41 mg/kg (DRUG), Ketamine 0.71 mg/kg (DRUG), Lorazepam 2 mg (DRUG).
Who is sponsoring clinical trial NCT01790490?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01790490 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01790490's enrollment target sits among peer trials
8 38th of 38 higher than 1 of 38 other Cocaine Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cocaine Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clavulanic Acid for the Treatment of Cocaine Use Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Disulfiram for Cocaine Abuse
COMPLETED · Phase 2
-
Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence
COMPLETED · Phase 2
-
Citalopram for Cocaine Dependence
COMPLETED · Phase 2
-
PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)
COMPLETED · Phase 2
-
Clinical Trial of Topiramate for Cocaine Addiction
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia